Wedbush analyst Yun Zhong has reiterated their bullish stance on RCKT stock, giving a Buy rating today.
Yun Zhong has given his Buy rating due to a combination of factors that highlight Rocket Pharmaceuticals’ promising outlook. The company’s recent updates indicate that its programs are progressing as planned, with particular focus on their AAV cardiovascular initiatives. The initial data from the Phase 1 study of RP-A601 for PKP2-ACM is expected to be released in the first half of 2025, alongside updates on RP-A501 for Danon disease, which could provide significant insights into the company’s clinical advancements.
Furthermore, Rocket Pharmaceuticals’ financial position appears robust, with an expected cash runway extending into the third quarter of 2026. This financial stability, coupled with the limited clinical risk associated with RP-A501 for Danon disease, supports a favorable risk/reward profile. The company’s strategic approach to value realization, particularly in its lentiviral programs, adds to the positive outlook. As a result, Yun Zhong reiterates an OUTPERFORM rating with a price target of $32 for RCKT.